Homophilic complex formation of CDCP1 via the extracellular CUB2 domain facilitates SFK activation and promotes cancer cell migration

TADASHI SAWAYAMA¹, KATSUHIKO NAKASHIMA², TOHRU ICHIMURA¹, RYUICHI SAKAI²³ and TAKAMASA UEKITA¹

¹Department of Applied Chemistry, National Defense Academy, Yokosuka 23908686; ²Division of Refractory and Advanced Cancer, National Cancer Center Research Institute, Tokyo 105-0045; ³Division of Biochemistry, Kitasato University School of Medicine, Kanagawa 252-0374, Japan

Received December 10, 2018; Accepted June 28, 2019

DOI: 10.3892/or.2019.7271

Abstract. CUB domain-containing protein 1 (CDCP1) is phosphorylated by Src family kinases (SFK), and is thought to serve an important role in tumor metastasis through downstream signaling subsequent to its interaction with protein kinase C δ. The present study investigated the mechanisms of activation for CDCP1 signaling, and demonstrated that CDCP1 is able to activate SFK via a homophilic complex of the extracellular complement C1r/C1s, urchin embryonic growth factor, bone morphogenetic protein 1 (CUB) 2 domain. Deletion of the extracellular CDCP1 region abolished homophilic complex formation of CDCP1 and the ability to promote cancer cell migration. When the culture medium was supplemented with recombinant CUB2 domain protein fused with maltose binding protein (rMBP-CUB2), CDCP1 homophilic complex formation was effectively inhibited. rMBP-CUB2 also inhibited SFK activation and the migratory capacity of invasive human lung adenocarcinoma A549 cells, and human pancreatic BxPC3 cells. These findings demonstrated a novel function for the extracellular CUB2 domain of CDCP1, promoting cancer cell migration via SFK activation on the plasma membrane. It was also indicated that the region blocking the homophilic binding site may be a potential therapeutic target against CDCP1-dependent tumor invasion.

Introduction

Src family kinases (SFKs) comprise the largest family of non-receptor tyrosine kinases (1). Activated SFKs initiate numerous signaling pathways; under the control of extracellular stimuli, these pathways serve important roles in various cellular functions, including proliferation, migration and survival (2). SFK activation results in the phosphorylation of Tyr in the kinase domain (3), and SFK activity is regulated by a phosphotyrosine ligand with a higher affinity for the SH2 domain (1). Studies have demonstrated increased SFK activity in a number of human cancers (4), thus the analysis of SFK activation is important to understand tumor progression.

CDCP1 possesses three complement C1r/C1s, urchin embryonic growth factor bone morphogenetic protein 1 (CUB) domains in its extracellular domain (ECD), which may be involved in protein-protein interactions (15-17). Therefore, CDCP1 may form a homophilic complex at the plasma membrane through its ECD. CUB1, the domain
located furthest from the transmembrane domain, is cleaved and released, and has been detected in the urine of patients with cancer (18,19). CDCP1 cleavage in the ECD induces cell migration in triple-negative breast cancer cells (18). These findings demonstrated that the extracellular CUB domains of CDCP1 potentially regulate tumor cell migration by promoting CDCP1 signaling; however, the functional mechanism of this activation is not yet understood. The present study investigated how CUB domains stimulate CDCP1 signaling. Utilizing recombinant proteins, it was demonstrated for the first time that the extracellular CUB domain of CDCP1 is the formation site of the CDCP1 homophilic complex. This provides novel information on the role of the CUB2 domain in regulating intracellular CDCP1 signaling.

**Materials and methods**

**Antibodies.** Anti-HA (Y-11; cat. no. sc-805; 1:300), anti-HA-horseradish peroxidase (HRP)-conjugated (Y-11 HRP; cat. no. sc-805 HRP; 1:500), anti-c-Src (SRC2; cat. no. sc-18; 1:4,000) and anti-PKCδ (C-20; cat. no. sc-937; 1:4,000) antibodies were purchased from Santa Cruz Biotechnology. Anti-FLAG M2 fluorescein isothiocyanate-conjugated (cat. no. F-4049; 1:600), anti-FLAG M2 peroxidase-conjugated specific (cat. no. A8592; 1:4,000) and anti-α tubulin (cat. no. T5168; 1:10,000) antibodies were purchased from Sigma-Aldrich (Merck KGaA). An anti-maltose-binding protein (MBP) antibody (cat. no. E8032 1:10,000) was purchased from New England BioLabs, Inc. Anti-phospho-Src family (Tyr 416, and 2101; 1:2,000) and anti-phospho-PKCδ (Tyr 311; cat. no. 2055; 1:2,000) antibodies were purchased from Cell Signaling Technology, Inc. HRP-conjugated anti-mouse IgG (cat. no. NA931V; 1:4,000) and anti-rabbit IgG (cat. no. NA934V; 1:4,000) antibodies were purchased from GE Healthcare. Alexa Fluor 488 goat anti-mouse (cat. no. A11011; 1:800) and Alexa Fluor 546 goat anti-rabbit (cat. no. A11010; 1:800) antibodies were purchased from Thermo Fisher Scientific, Inc. Rabbit polyclonal anti-CDCP1 antibody was prepared as described previously (9).

**Expression plasmids.** pcDNA3.1 expression plasmids (Thermo Fisher Scientific, Inc.,) encoding human CDCP1 with a C-terminal FLAG or HA tag, and the CDCP1 rescue sequence that introduces silent mutations that are not suppressed by CDCP1 siRNA (CDCP1res-F and CDCP1res-HA, respectively), have been described previously (13). The ECD-deleted mutant plasmid with C-terminal FLAG tag (∆ECD-F) was prepared as described previously (9). A system for the stable, siRNA-induced suppression of CDCP1 expression was constructed using the Block IT Pol II miRNA Expression Vector kit (Invitrogen; Thermo Fisher Scientific, Inc.,) encoding human CDCP1 with a C-terminal FLAG or HA tag, and the CDCP1 rescue sequence that introduces silent mutations that are not suppressed by CDCP1 siRNA (CDCP1res-F and CDCP1res-HA, respectively), have been described previously (13). The ECD-deleted mutant plasmid with C-terminal FLAG tag (∆ECD-F) was prepared as described previously (9). A system for the stable, siRNA-induced suppression of CDCP1 expression was constructed using the Block IT Pol II miRNA Expression Vector kit (Invitrogen; Thermo Fisher Scientific, Inc.,) encoding human CDCP1 with a C-terminal FLAG or HA tag, and the CDCP1 rescue sequence that introduces silent mutations that are not suppressed by CDCP1 siRNA (CDCP1res-F and CDCP1res-HA, respectively), have been described previously (13). The ECD-deleted mutant plasmid with C-terminal FLAG tag (∆ECD-F) was prepared as described previously (9).

**Immunofluorescence staining.** For immunostaining, cells cultured on cover glasses were washed with phosphate-buffered saline (PBS) at 37°C and fixed with 4% paraformaldehyde in PBS for 10 min at room temperature. The cells were washed again with PBS and permeabilized with 0.25% Triton X-100 in PBS. The cells were blocked with Blocking One (Nacalai Tesque, Inc.,) for 40 min, and co-localization was analyzed using a confocal laser-scanning microscope (FLUOVIEW FV10i) and the FV10-ASW software ver. 4.1 ‘Co-Localization’ (Olympus Corporation). At a certain threshold, the FV10-ASW software converts the pixels of the area co-stained with two fluorescent substances into a white dot; the ratio of white dot pixels to total pixels is then determined, and the pixel rate corresponds to the co-localization area value.

**Western blotting and immunoprecipitation.** Cell lysates were prepared in PLC buffer [10 mM Tris-HCl (pH 7.5), 5 mM EGTA, 150 mM NaCl, 1% Triton X-100, 10% glycerol and 1 mM sodium orthovanadate]. The lysates were centrifuged at 20,630 x g for 20 min at 4°C, and the supernatants were collected. Protein concentrations were measured using a BCA Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.).

**For immunoprecipitation, the lysates (1 µg/µl; 350 µl) were incubated with anti-FLAG M2 affinity gel (20 µl) or anti-HA antibody conjugated with Protein G Sepharose 4 Fast Flow gel (30 µl) on ice for 1 h. The anti-FLAG M2-protein or anti-HA-protein complexes were then harvested and washed three times with PLC lysis buffer. The total amount of each immunoprecipitated sample was separated by 8% SDS-PAGE gel and visualized using western blotting.**

For western blotting, the samples were transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon-P; EMD Millipore). After blocking with blocking buffer (Blocking One; Nacalai Tesque) the membranes were probed with primary antibodies (anti-CDCP1, anti-α tubulin, anti-FLAG M2 and anti-HA antibody conjugated with Protein G Sepharose 4 Fast Flow gel (30 µl) on ice for 1 h. The anti-FLAG M2-protein or anti-HA-protein complexes were then harvested and washed three times with PLC lysis buffer. The total amount of each immunoprecipitated sample was separated by 8% SDS-PAGE gel and visualized using western blotting.

**Cell culture and transfection.** Human lung adenocarcinoma A549 and human pancreatic cancer BxPC3 cell lines were cultured in RPMI 1640 (Sigma-Aldrich; Merck KGaA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) at 37°C, 5% CO2. A549 miCDCP1 cells with suppressed CDCP1 expression, and A549 miLacZ cells (the control cells from the Block IT Pol II miRNA Expression Vector kit) were used as described previously (9).

For transfection, cells were seeded at 5x106 cells/well of a 24-well plate, prior to a 24-h incubation period. The cells were transfected with the expression plasmids (CDCP1res-F, 5 µg; CDCP1res-HA, 5 µg; and ΔECD-F, 1 µg) using Lipofectamine™ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. The transfected cells were selected in the presence of 800 µg/ml G418 sulfate (EMD/Merck KGaA) for one month prior to experimentation.

**Expression plasmids.** pcDNA3.1 expression plasmids (Thermo Fisher Scientific, Inc.,) encoding human CDCP1 with a C-terminal FLAG or HA tag, and the CDCP1 rescue sequence that introduces silent mutations that are not suppressed by CDCP1 siRNA (CDCP1res-F and CDCP1res-HA, respectively), have been described previously (13). The ECD-deleted mutant plasmid with C-terminal FLAG tag (∆ECD-F) was generated by inverse PCR using the KOD-Plus-Mutagenesis kit (Toyobo Life science) per the manufacturer’s protocol.

A system for the stable, siRNA-induced suppression of CDCP1 expression was constructed using the Block IT Pol II miRNA Expression Vector kit (Invitrogen; Thermo Fisher Scientific, Inc.,) according to the manufacturer’s instructions. The following primers were used to generate the CDCP1 miRNA plasmid (miCDCP1): Forward, 5'-TGCTGAAATCGTGATTTTGATAGTCGCTTTTTGCCCACGTTTGGC CACTGACTGACCCGCAAAGAAGAAGATT-3', and reverse, 5'-CCTGAAAATCGCTGATGTTAGTGTCGTCAGTGCGCAGTCA GTCAGTGCCCAAACATCGCCACAGAAGCAACATT-3'. The LacZ miRNA plasmid was selected as the negative control, and was constructed using the following primers: Forward, 5'-TGGCTGAAATCGTGATTTTGATAGTCGCTTTTTGCCCACGTTTGGC CACTGACTGACCCGCAAAGAAGAAGATT-3', and reverse, 5'-CCTGAAAATCGCTGATGTTAGTGTCGTCAGTGCGCAGTCA GTCAGTGCCCAAACATCGCCACAGAAGCAACATT-3'.
peroxidase-conjugated, anti-HA, anti-HA-HPK-conjugated, anti-MBP, anti-c-Src, Anti-phospho-Src family, anti-PKCδ and anti-phospho-PKCδ) at room temperature for 1 h to detect the indicated proteins. After washing three times with TBS-T (0.05% Tween-20 in TBS), the membranes were further probed with the corresponding secondary antibodies at room temperature for 30 min. The blots were visualized using the Western Lightning Plus-ECL kit (PerkinElmer, Inc.) and images were captured with the myECL imager (Thermo Fisher Scientific, Inc.). The proteins were subsequently quantified using ImageJ software, version 1.50i (National Institutes of Health).

Scratch wound-healing assay. To investigate the wound-healing effect, A549 miCDCP1 cells transfected with CDCP1res-F, ΔECD-F or mock (pcDNA3.1) plasmids were seeded in RPMI (10% FBS) at 1x10⁵ cells/well in 6-well, and incubated until confluent. Each monolayer was scratched to create a wound of ~600 µm. After washing three times with PBS to remove cell debris, 5 ml RPMI (10% FBS) was added to each well. Images were captured by phase-contrast microscopy (BZ-X 710; Keyence Corporation) at 0 and 12 h for BxPC3 cells, and after 24 h for A549 cells. Wound recovery was measured with the BZ-X analyzer. Cell migration was evaluated as the mean of the migration length in three independent experiments. BxPC3 cell migration was analyzed in the same manner, with the only difference being the timing of image capture (at 0 and 12 h).

MBP protein expression and far-western blotting. To create MBP constructs, the amplified CUB2 and CUB3 domain sequences of CDCP1 were inserted into the pMAL-c5x expression vector (New England BioLabs, Inc.). PCR was performed with the following primers: rMBP-CUB2 forward, 5' -CGC ATA TGT GCA CAG ACC ACC GGT ACT GC-3', and reverse, 5'-GCG AAT TCA ACG CCT TCC TCT TTG AAA TAA G-3'; and rMBP-CUB3 forward, 5'-GCC ATA TGG AGG AAG GCG TTT TCA CGG TGA C-3', and reverse, 5'-CGG AAT TCT GGG GTA TCA CGG TGA C-3'. Protein expression and affinity purification with amylose resin were performed in accordance with the manufacturer's protocol.

For far-western blotting, each rMBP protein (3 µg) was blotted onto a PVDF membrane. After blocking with blocking buffer for 1 h, each cell lysate expressing CDCP1res-F or ΔECD-F (10 µg/ml with TBS-Tween 20) was incubated with the membrane for 1 h. After washing three times with TBS-Tween 20, the membrane was used for western blotting.

Statistical analysis. All data are presented as the mean ± standard deviation; ANOVA followed by Tukey's test was used for multiple comparisons among sample groups. P<0.05 was considered to indicate a statistically significant difference.

Results

CDCP1 forms a homophilic complex via the ECD. A previous study indicated that CDCP1 was capable of forming dimers within the cell (20). To verify this phenomenon, FLAG-tagged CDCP1 (CDCP1res-F) and HA-tagged CDCP1 (CDCP1res-HA) (Fig. 1A) were co-expressed in A549 miCDCP1 cells, where endogenous CDCP1 expression was stably suppressed (26.1±4.0%; Fig. 1B). CDCP1res-F was immunoprecipitated with an anti-FLAG M2 antibody. As shown in Fig. 1C, CDCP1res-HA was co-immunoprecipitated with CDCP1res-F (lane 5), and the same result was observed by immunoprecipitation with the anti-HA antibody (lane 8). This indicated that differentially tagged CDCP1 molecules formed a complex with each other. To determine whether the ECD of CDCP1 was important for complex formation, ΔECD-F (which still contained the N-terminal signal sequence and is expressed at the cell membrane) was co-expressed with CDCP1res-HA (Fig. 1A) and subjected to immunoprecipitation and western blotting with anti-FLAG M2 and anti-HA antibodies. CDCP1res-HA was associated with CDCP1res-F; however, by comparison, less association was detected with CDCP1res-HA and ΔECD-F (Fig. 1C, lanes 6 and 9). In addition, two control IgG antibodies did not immunoprecipitate with CDCP1res-F and CDCP1res-HA (Fig. 1C, lanes 11 and 14).

CDCP1 homophilic complex formation on cells was also investigated. CDCP1res-HA and either CDCP1res-F or ΔECD-F was co-expressed in A549 miCDCP1 cells, and localization was examined by immunostaining. CDCP1res-F and CDCP1res-HA were detected on the plasma membrane and ruffling edge (Fig. 2A, inserts a, b, and f). CDCP1res-F and CDCP1res-HA were also primarily co-localized at the plasma membrane and the periphery of cells (Fig. 2A, insert d). Although ΔECD-F was expressed around the plasma membrane (Fig. 2A, insert e), it was localized mainly at a region of the cell surface that was different from the region at which CDCP1res-HA was localized (Fig. 2A, insert h). To monitor the level of co-localization of CDCP1 variants at the cell surface, the co-localization areas were quantified. The co-localization of each CDCP1 variant on the cell membrane is shown as the area of white dots detected by FV10-ASW software (Fig. 2B, inserts a and b). The co-localization area of CDCP1res-F and CDCP1res-HA (6.89±1.95%) was greater than that of ΔECD-F and CDCP1res-HA (1.63±0.76%) (Fig. 2B). Taken together, these results suggested that the ECD is required for CDCP1 homophilic complex formation at the cell surface.

CDCP1 ECD regulates lung cancer cell migration. Previous reports have suggested that CDCP1 is important for the regulation of cancer cell migration (13). It was thus hypothesized that CDCP1 formed a homophilic complex via the ECD on the cell surface to regulate cell migration. A scratch wound-healing assay was used to assess the significance of the CDCP1 ECD in cancer cell migration (Fig. 3A). Cells with CDCP1 suppression exhibited significantly reduced migratory properties, compared with CDCP1-expressing cells (Fig. 3B, miLacZ vs. miCDCP1 Mock vector), as supported by a previous report (13). For the rescue experiments, CDCP1res-F and ΔECD-F vectors were transfected into A549 miCDCP1 cells. Cell migration was recovered by the CDCP1res-F vector, but not by the ΔECD-F mutant vector (Fig. 3B). This result demonstrated that the CDCP1 ECD is required for cancer cell migration.
cellular CUB2 and/or CUB3 domains of CDCP1 served a role in the regulation of homophilic complex formation. To test this hypothesis, recombinant CUB2 or CUB3 domains were fused with the MBP (rMBP; rMBP-CUB2 and rMBP-CUB3, respectively) (Fig. 4A). The rMBP fusion proteins (3 µg each) were immobilized onto a PVDF membrane (Fig. 4B, rMBP proteins) and blotted with A549 miCDCP1 cell lysates expressing CDCP1res-F or ΔECD-F. Each protein was visualized.
using an anti-FLAG M2 antibody. The results showed that CDCP1res-F was able to bind rMBP-CUB2; however, it was minimally bound to rMBP-CUB3 (Fig. 4B, CDCP1res-F). By contrast, ΔECD-F did not bind to either rMBP fusion protein (Fig. 4B, ΔECD-F), and neither CDCP1 variant bound to rMBP (Fig. 4B, CDCP1res-F and ΔECD-F). To confirm the interaction between CDCP1 and purified recombinant CUB proteins, each CUB protein was added to the culture medium of A549 miCDCP1 cells expressing CDCP1res-HA, and the binding capacity of the CUB products was determined using immunostaining. CDCP1res-HA localization was detected at the plasma membrane and the ruffling edge, with minimal differences in CDCP1-HA expression levels between samples (Fig. 4C, inserts a, e and i). rMBP-CUB2 was co-localized with CDCP1res-HA at the plasma membrane (Fig. 4C, insert g), but rMBP and rMBP-CUB3 rarely co-localized (Fig. 4C, inserts c and k). The co-localization of each rMBP fusion protein with CDCP1res-HA was determined using FV10-ASW software, and is indicated by the white dotted region (Fig. 4C, inserts d, h and l). The co-localization area of rMBP-CUB2 with CDCP1res-HA (3.32±0.46%) was greater than that of rMBP or rMBP-CUB3 with CDCP1res-HA (0.17±0.08 and 0.78±0.39%, respectively) (Fig. 4D). These results indicated that rMBP-CUB2 was the primary binding partner of CDCP1.

The potential rMBP-CUB2-induced inhibition of CDCP1 homophilic complex formation was also investigated. A549 miCDCP1 cells were transfected with CDCP1res-F and CDCP1res-HA expression vectors, and rMBP-CUB2 or rMBP-CUB3 proteins were added at the indicated concentrations (0, 5 and 10 µg/ml). No significant difference in the CDCP1 expression level was observed in these cell lines using immunostaining. CDCP1res-HA localization was detected at the plasma membrane and the ruffling edge, with minimal differences in CDCP1-HA expression levels between samples (Fig. 4C, inserts a, e and i). rMBP-CUB2 was co-localized with CDCP1res-HA at the plasma membrane (Fig. 4C, insert g), but rMBP and rMBP-CUB3 rarely co-localized (Fig. 4C, inserts c and k). The co-localization of each rMBP fusion protein with CDCP1res-HA was determined using FV10-ASW software, and is indicated by the white dotted region (Fig. 4C, inserts d, h and l). The co-localization area of rMBP-CUB2 with CDCP1res-HA (3.32±0.46%) was greater than that of rMBP or rMBP-CUB3 with CDCP1res-HA (0.17±0.08 and 0.78±0.39%, respectively) (Fig. 4D). These results indicated that rMBP-CUB2 was the primary binding partner of CDCP1.
These results suggested that the extracellular CUB2 domain of CDCP1 regulates homophilic complex formation at the plasma membrane.

The CUB2 domain of CDCP1 regulates cancer cell migration via SFK activation. Since rMBP-CUB2 effectively inhibited CDCP1 homophilic complex formation, the effect of rMBP-CUB2 on intracellular SFK-CDCP1-PKCδ signaling in parental A549 cells was investigated. Neither rMBP protein affected cell survival (Fig. S2), though SFK activation was reduced in A549 miCDCP1 cells, whose CDCP1 expression was suppressed (Fig. 5A). Notably, Tyr416 (Y416) phosphorylation of SFK, which is an indicator of SFK activation, was suppressed following the addition of rMBP-CUB2 (Fig. 5B; SFK, lane 3), but not that of rMBP or rMBP-CUB3 (Fig. 5B, SFK, lanes 2 and 4). In addition, phosphorylation of PKCδ, a downstream signal molecule of SFK, was reduced by the addition of rMBP-CUB2 (Fig. 5B PKCδ lane 3), but not rMBP or rMBP-CUB3 (Fig. 5B, PKCδ, lanes 2 and 4). Comparable results were observed in the pancreatic cancer cell line BxPC3 (Fig. S3).

Finally, the effect of rMBP-CUB2 on cell migration was examined using a scratch wound-healing assay (Fig. S4). Cell migration was reduced by treatment with rMBP-CUB2 in both the A549 and BxPC3 cell lines; by contrast, rMBP and rMBP-CUB3 did not affect cell migration (Fig. 5C). These results indicated that the extracellular CUB2 domain of CDCP1 regulates cell migration by promoting SFK activation.

Discussion

In the present study, the formation of a CDCP1 homophilic complex via the CUB2 domain was demonstrated at the cell surface. This formation allows for the tighter molecular arrangement of signaling molecules at the cell surface. CDCP1 mediates the phosphorylation of PKCδ by active SFK, thus, it is
conceivable that one of the CDCP1 molecules in the complex acts as an active SFK receptor, and that the other molecule serves as a PKCδ receptor. In the present study, co-expression of CDCP1res-F with CDCP1res-HA demonstrated that the formation of the CDCP1 complex (Fig. 1) may generate an intracellular signal (Fig. 5B, lane 1). Previous reports have...
indicated that cleavage between the CUB1 and CUB2 domains of the CDCP1 ECD is important for dimerization, and that the CUB2 domain may be a key region for homophilic complex formation (18,21). In the present study, rMBP-CUB2 prevented CDCP1 homophilic complex formation (Fig. 4E) and decreased PKCδ phosphorylation (Fig. 5B, PKCδ lane 3); therefore, the interaction between CDCP1 molecules via the CUB2 domain is most likely a mechanism for initiating SFK-CDCP1-PKCδ signaling by clustering the receptor for active SFK and PKCδ at the cell membrane. In addition, Hooper et al (5) revealed that CDCP1 possessed 14 putative N-glycosylation sites. The released CUB1 region of CDCP1 (30-368 residues) has a greater...
number of putative glycosylation sites than the remaining ECD (Fig. S5). Thus, it is speculated that the CUB1-containing region possessing these glycosylation sites may be a regulator for SFK-CDCP1-PKCδ signaling.

SFK activation is important for SFK-CDCP1-PKCδ signaling (9). CDCP1 phosphorylation is increased in metastatic cancer cells; however, the mechanism of enhanced phosphorylation is not clear. Substrates such as p130Cas and Ossa can activate SFK by associating with their phosphorylated regulatory domains (22,23). CDCP1 can also activate SFK, possibly via a similar mechanism (24). In the present study, rMBP-CUB2 prevented CDCP1 homophilic complex formation (Fig. 4E) and SFK activation in cancer cells (Fig. 5B SFK lane 3). Therefore, CDCP1 accumulation at the cell membrane via the essential CUB2 domain may be required for SFK activation. The CUB2-mediated interaction of CDCP1 most likely promotes the activation of SFK by clustering inactive SFK molecules and CDCP1 within the cell membrane. It is not clear whether dimer formation is sufficient for effective signal transduction, or if oligomerization would enhance signaling activity. Furthermore, since SFK may be activated by the homophilic complex of phosphorylated CDCP1, analysis of the initial activation mechanism of SFK is required. Nonetheless, the CUB2 domain interaction between CDCP1 molecules appears to be critical for SFK activation.

In the present study, a regulatory mechanism of CDCP1 in cancer cell migration was revealed. Consistent with a previous report by Miyazawa et al (13), the CDCP1 ECD was revealed to regulate cell migration (Fig. 3). Furthermore, a positive correlation was observed between CDCP1 complex formation via the CUB2 domain and cell migration in different cancer cell lines (Figs. 5, S3 and S4). SFK-mediated CDCP1 phosphorylation is a requirement for cell migration (13). Thus, the mechanisms of CDCP1 homophilic complex formation-induced SFK activation via CUB2 may regulate cell migration mediated by intracellular SFK-CDCP1-PKCδ signaling.

The extracellular CUB domain is thought to mediate interactions between various proteins (15). A number of integrins have been reported to influence CDCP1 phosphorylation (25). Moreover, a possible association between N-cadherin (which is involved in epithelial-mesenchymal transition) and CDCP1 has also been reported (26). In addition to these previous findings, the present study delineated a role for the CUB2 domain in CDCP1 homophilic complex formation, and in the regulation of cell migration. Therefore, the CUB2 domain may be broadly involved in molecular interactions that mediate biological functions such as cell migration.

Kollmorgen et al (20) suggested that CDCP1 may form homophilic dimer complexes via its transmembrane and cytoplasmic domains. In the present study, the interaction between CDCP1res-HA and AECD-F was observed (Fig. 1); however, the motility of cancer and A549 miCDCP1 cells was markedly reduced (Fig. 3). This suggests that dimer formation by transmembrane and cytoplasmic domains may regulate cancer cell functions other than migration. Therefore, further studies with CDCP1 variants are required to investigate the effects of this additional binding site on cancer cell function.

The present study suggested that the CDCP1 CUB2 domain may act as a therapeutic target. Recombinant proteins containing the CUB2 and CUB3 domains of CDCP1 are able to suppress cell migration (18), but the required domain was previously unknown. Herein, it was demonstrated that rMBP-CUB2 decreased SFK-CDCP1-PKCδ signaling, and the migration of A549 and BxPC3 cell (Figs. 5, S3 and S4). Also, an interaction between rMBP-CUB3 and CDCP1res-HA was detected (Fig. 4B); however, rMBP-CUB3 did not effectively inhibit homophilic complex formation (Fig. 4E) or cancer cell migration (Fig. 5C). In addition, the comparison of amino acid sequences of each CUB domain showed low rates of homology (Fig. S6). Although, the possibility that CUB3 is critical to CDCP1 homophilic complex formation cannot be excluded, as the current data support cell migration primarily via the extracellular CUB2 domain. A previous report detailed the homophilic complex of MMP14 formed by the hemopexin-like (PEX) domain. Expression of the exogenous PEX domain also resulted in dose-dependent inhibition of cancer cell invasion via cell surface activation of proMMP-2 (27). Therefore, the present study supported that the CUB2 domain may present a novel target for the inhibition of CDCP1 homophilic complex formation and cell migration, thus contributing to the suppression of cancer cell invasion.

The present study indicated that the CUB2 domain of CDCP1 stimulates SFK activation through homophilic binding, and that it also regulates cancer cell migration. In addition, molecules that inhibit CDCP1 homologous complex formation, such as rMBP-CUB2, may be viable therapeutic candidates to combat invasive cancer.

Acknowledgements

Not applicable.

Funding

The present study was supported by a Grant-in-Aid for Scientists by the Ministry of Education, Culture, Sports, Science and Technology of Japan [JSPS KAKENHI, grant no. 15K06850 (TU)] and the National Cancer Center Research Development Fund [grant no. 23-B-24 (TU)].

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

TS, KN, TI, RS and TU made substantial contributions to conception and design or execution and interpretation of the data. TS and TU analyzed and interpreted the data regarding CDCP1 homophilic complex formation via CUB2 domain. TS performed the examination of cell migration and SFK activation and was a primary contributor to the manuscript writing. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.
Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References